RA Capital Healthcare Fund LP's Form 4 filing
Janux Therapeutics, Inc. (JANX) · filed Jul 21, 2023
- Accession no.
- 0001104659-23-083069
- Filed
- Jul 21, 2023, 4:31 PM ET
- Trade date
- Jul 19, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $6.17M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | Director, 10% Owner |
| Ra Capital Management, L.P.CIK 0001346824 | Director, 10% Owner |
| Kolchinsky PeterCIK 0001384859 | Director, 10% Owner |
| Shah Rajeev M.CIK 0001619841 | Director, 10% Owner |
| RA Capital Nexus Fund II, L.P.CIK 0001825376 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 19, 2023 | Common Stock | PPurchaseAcquired | +495,008 | $12.46F1 | +$6,167,799.68 | 8,117,246 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 19, 2023 | Common Stock | PPurchaseAcquired | +503,226 | $12.46 | +$6,269,692.73 | 503,226 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Acquired from the Issuer pursuant to the public offering described in the Issuer's Prospectus filed with the Securities and Exchange Commission on July 18, 2023.
Referenced by the price of 1 transaction in Table I.
Remarks
Jake Simson, a Partner of the Adviser, serves on the Issuer's board of directors.